Evidence map›Paper›PMID 34339738›Full record

ArticleThe Journal of biological chemistry2021

Epistatic interactions promote persistence of NS3-Q80K in HCV infection by compensating for protein folding instability.

Georg Dultz, Sanjay K Srikakulam, Michael Konetschnik, Tetsuro Shimakami, Nadezhda T Doncheva, Julia Dietz, Christoph Sarrazin, Ricardo M Biondi, Stefan Zeuzem, Robert Tampé and 2 more

Open access · goldAbstract read
In one paragraph

Article in The Journal of biological chemistry, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.5field-weighted citation impact, top 37% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 4 countries.

Georg DultzDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Sanjay K SrikakulamHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University Campus, Saarbrücken, Germany; Graduate School of Computer Science, Saarland University, Saarbrücken, Germany; Interdisciplinary Graduate School of Natural Product Research, Saarland University, Saarbrücken, Germany.
Michael KonetschnikDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Tetsuro ShimakamiDepartment of Gastroenterology, Kanazawa University Hospital, Kanazawa, Japan.
Nadezhda T DonchevaNovo Nordisk Foundation Center for Protein Research, University of Copenhagen, Copenhagen, Denmark.
Julia DietzDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Christoph SarrazinDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany.
Ricardo M BiondiMolecular Targeting, Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA) - CONICET - Partner Institute of the Max Planck Society, Buenos Aires, Argentina.
Stefan ZeuzemDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; University Center for Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany.
Robert TampéInstitute of Biochemistry, Biocenter, Goethe University Frankfurt, Frankfurt am Main, Germany.
Olga V KalininaHelmholtz Institute for Pharmaceutical Research Saarland (HIPS), Helmholtz Centre for Infection Research, Saarland University Campus, Saarbrücken, Germany; Medical Faculty, Saarland University, Homburg, Germany; Center for Bioinformatics, Saarland Informatics Campus, Saarbrücken, Germany.
Christoph WelschDepartment of Internal Medicine 1, Goethe University Hospital Frankfurt, Frankfurt am Main, Germany; University Center for Infectious Diseases, University Hospital Frankfurt, Frankfurt am Main, Germany. Electronic address: christoph.welsch@kgu.de.
Goethe University Frankfurt · DEHelmholtz Centre for Infection Research · DEBiomedicine Research Institute of Buenos Aires - CONICET - Partner Institute of the Max Planck Society · ARKanazawa University Hospital · JPUniversity of Copenhagen · DK

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The Q80K polymorphism in the NS3-4A protease of the hepatitis C virus is associated with treatment failure of direct-acting antiviral agents. This polymorphism is highly prevalent in genotype 1a infections and stably transmitted between hosts. Here, we investigated the underlying molecular mechanisms of evolutionarily conserved coevolving amino acids in NS3-Q80K and revealed potential implications of epistatic interactions in immune escape and variants persistence. Using purified protein, we characterized the impact of epistatic amino acid substitutions on the physicochemical properties and peptide cleavage kinetics of the NS3-Q80K protease. We found that Q80K destabilized the protease protein fold (p < 0.0001). Although NS3-Q80K showed reduced peptide substrate turnover (p < 0.0002), replicative fitness in an H77S.3 cell culture model of infection was not significantly inferior to the WT virus. Epistatic substitutions at residues 91 and 174 in NS3-Q80K stabilized the protein fold (p < 0.0001) and leveraged the WT protease stability. However, changes in protease stability inversely correlated with enzymatic activity. In infectious cell culture, these secondary substitutions were not associated with a gain of replicative fitness in NS3-Q80K variants. Using molecular dynamics, we observed that the total number of residue contacts in NS3-Q80K mutants correlated with protein folding stability. Changes in the number of contacts reflected the compensatory effect on protein folding instability by epistatic substitutions. In summary, epistatic substitutions in NS3-Q80K contribute to viral fitness by mechanisms not directly related to RNA replication. By compensating for protein-folding instability, epistatic interactions likely protect NS3-Q80K variants from immune cell recognition.

Indexed as

Epistasis, GeneticAmino Acid SubstitutionGenes, ViralHepacivirusHepatitis CHumansMolecular Dynamics SimulationMutationPolymorphism, GeneticViral Nonstructural ProteinsViral Nonstructural Proteinshepatitis C virusimmune escapeprotein evolutionprotein foldingresistance mutationserine protease (NS3-4A)viral fitness

Identifiers

PMID34339738
PMCPMC8405986
OpenAlexW3192948021

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.